The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.

[1]  S. Hirohashi,et al.  Overexpression of c‐erbB‐2 protein in gastric cancer. Its correlation with long‐term survival of patients , 1993 .

[2]  N. Yamanaka,et al.  Relationship of C‐erbB‐2 protein expression and gene amplification to invasion and metastasis in human gastric cancer , 1993, Cancer.

[3]  T. Kameya,et al.  An immunohistochemical study of c‐erbb‐2 protein in gastric carcinomas and lymph‐node metastases: Is the c‐erbB‐2 protein really a prognostic indicator? , 1993, International journal of cancer.

[4]  T. Wobbes,et al.  Evaluation of seven tumor markers (CA 50, CA 19‐9, CA 19‐9 TruQuant, CA 72‐4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma , 1992, Cancer.

[5]  W. Gullick,et al.  c‐erbB‐2 proto‐oncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archival material , 1991, International journal of cancer.

[6]  Takuma Sasaki,et al.  Expression of C‐erbB‐2 oncoprotein in gastric carcinoma. Immunoreactivity for C‐erbB‐2 protein is an independent indicator of poor short‐term prognosis in patients with gastric carcinoma , 1991, Cancer.

[7]  M. Enjoji,et al.  Distribution of β‐human chorionic gonadotropin‐positive cells in noncancerous gastric mucosa and in malignant gastric tumors , 1990, Cancer.

[8]  H. Wieand,et al.  A phase ii study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer , 1990, Cancer.

[9]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[11]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[12]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[13]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[14]  M. Mai,et al.  [Clinicopathological study of AFP producing gastric cancer--significance of AFP in gastric cancer]. , 1987, Nihon Geka Gakkai zasshi.

[15]  C. Haglund,et al.  Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. , 1987, British Journal of Cancer.

[16]  H. Egami,et al.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. , 1987, Gut.

[17]  H. Egami,et al.  Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive System , 1986, The American journal of the medical sciences.

[18]  K. Hirao,et al.  Human chorionic gonadotropin in normal, inflammatory, and carcinomatous gastric tissue. , 1985, Gastroenterology.

[19]  R. Tubbs,et al.  Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen , 1985, Cancer.

[20]  R. Jakesz,et al.  Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. , 1985, Cancer detection and prevention.

[21]  P. Wilkinson,et al.  Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. , 1984, British Journal of Cancer.

[22]  T. Klug,et al.  Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank , 1984, International journal of cancer.

[23]  C. Haglund,et al.  Comparison of a new tumour marker, CA 199TM, with a-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases , 2004 .

[24]  E. Tahara,et al.  HUMAN CHORIONIC GONADOTROPIN IN HUMAN GASTRIC CARCINOMA , 1983 .

[25]  J. Beatty,et al.  Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer. , 1979, Archives of surgery.

[26]  D. Skinner,et al.  A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms , 1979, The British journal of surgery.

[27]  J. Shuster,et al.  Carcinoembryonic antigen (CEA) in clinical medicine. Historical perspectives, pitfalls and projections , 1978, Cancer.

[28]  Ding‐Shinn Chen,et al.  Serum alphafetoprotein in hepatocellular carcinoma , 1977, Cancer.

[29]  M. Ostrander,et al.  Human chorionic gonadotrophins (hCG) in nontrophoblastic neoplasms. Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasms , 1976, Cancer.

[30]  T. Waldmann,et al.  α-Fetoprotein in Nonneoplastic Hepatic Disorders , 1975 .

[31]  T. Waldmann,et al.  alpha-fetoprotein in noneoplastic hepatic disorders. , 1975, JAMA.

[32]  T. Waldmann,et al.  Serum α-Fetoprotein in Patients with Neoplasms of the Gastrointestinal Tract , 1975 .

[33]  B. Weintraub,et al.  Placental proteins and their subunits as tumor markers. , 1975, Annals of internal medicine.

[34]  T. Waldmann,et al.  The use of a radioimmunoassay for alpha‐fetoprotein in the diagnosis of malignancy , 1974, Cancer.

[35]  G. Braunstein,et al.  Ectopic production of human chorionic gonadotrophin by neoplasms. , 1973, Annals of internal medicine.